Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Solid vs Crushed/Dissolved Biktarvy in Healthy Volunteers
NCT04244448Phase 1Completed
- Sponsor
- CHU Caen Normandie
- Start
- Dec 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) (3 arms), sponsored by CHU Caen Normandie. Primary endpoints: Plasma concentration of each of the three active ingredients in Biktarvy, Half-life elimination of each of the three active ingredients in Biktarvy and 1 more. Started Dec 2019; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04244448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04244448.